Key result
Prediabetes was independently associated with increased risk of ASCVD, CKD, and heart failure, with risk gradients observed below the diabetes threshold.
Why the study?
Treatment guidelines for prediabetes focus on glycemic control and lifestyle management, but few evidence-based cardiovascular and kidney risk-reduction strategies exist for this population.
Do prediabetes and type 2 diabetes increase the risk of ASCVD, CKD, and heart failure in individuals without prevalent cardiovascular or kidney disease?
Cohort (n=336,709)
Do prediabetes and type 2 diabetes increase the risk of ASCVD, CKD, and heart failure in individuals without prevalent cardiovascular or kidney disease?
Answers are grounded in this paper and cite their sources.
Prediabetes and T2D are independently associated with increased risks of ASCVD, CKD, and heart failure, with risk gradients starting below the diabetes threshold.
BACKGROUND: Treatment guidelines for prediabetes primarily focus on glycemic control and lifestyle management. Few evidence-based cardiovascular and kidney risk-reduction strategies are available in this population. OBJECTIVES: This study sought to characterize cardiovascular and kidney outcomes across the glycemic spectrum. METHODS: Among participants in the UK Biobank without prevalent type 1 diabetes, cardiovascular disease, or kidney disease, Cox models tested the association of glycemic exposures (type 2 diabetes [T2D], prediabetes, normoglycemia) with outcomes (atherosclerotic cardiovascular disease [ASCVD], chronic kidney disease [CKD], and heart failure), adjusting for demographic, lifestyle, and cardiometabolic risk factors. RESULTS: Among 336,709 individuals (mean age: 56.3 years, 55.4% female), 46,911 (13.9%) had prediabetes and 12,717 (3.8%) had T2D. Over median follow-up of 11.1 years, 6,476 (13.8%) individuals with prediabetes developed ≥1 incident outcome, of whom only 802 (12.4%) developed T2D prior to an incident diagnosis. Prediabetes and T2D were independently associated with ASCVD (prediabetes: adjusted HR [aHR]: 1.11; 95% CI: 1.08-1.15; P < 0.001; T2D: aHR: 1.44; 95% CI: 1.37-1.51; P < 0.001), CKD (prediabetes: aHR: 1.08; 95% CI: 1.02-1.14; P < 0.001; T2D: aHR: 1.57; 95% CI: 1.46-1.69; P < 0.001), and heart failure (prediabetes: aHR: 1.07; 95% CI: 1.01-1.14; P = 0.03; T2D: aHR: 1.25; 95% CI: 1.14-1.37; P < 0.001). Compared with hemoglobin A1c (HbA1c) <5.0%, covariate-adjusted risks increased significantly for ASCVD above HbA1c of 5.4%, CKD above HbA1c of 6.2%, and heart failure above HbA1c of 7.0%. CONCLUSIONS: Prediabetes and T2D were associated with ASCVD, CKD, and heart failure, but a substantial gradient of risk was observed across HbA1c levels below the threshold for diabetes. These findings highlight the need to design risk-reduction strategies across the glycemic spectrum.
No takes yet. Share an insight, caveat, or question.
Honigberg et al. (2021) conducted a cohort in Prediabetes and Type 2 Diabetes (n=336,709). Prediabetes vs. Normoglycemia was evaluated on Atherosclerotic cardiovascular disease (ASCVD) (HR 1.11, 95% CI 1.08-1.15, p=<0.001). Prediabetes was independently associated with increased risk of ASCVD, CKD, and heart failure, with risk gradients observed below the diabetes threshold.
Synapse has enriched 10 related papers. Consider them for comparative context: